NBD AI Bulletin - Cathay Biotech (SH 688065, close price: 83.77 yuan) on August 11 released the half-year results. Operating income for the first half of 2022 was about 1.289 billion yuan, showing an increase of 13.53% from a year earlier. Net profit attributable to the shareholders of the listed company was about 336 million yuan, representing an increase of 7.71%. Basic earnings per share was 0.58 yuan, up 7.41% from the previous year.
In 2021, the operating income of Cathay Biotech mainly came from the synthetic biomaterials industry (98.01%).
The president and chairman of Cathay Biotech is Xiucai Liu (Liu Xiucai), male, 65 years old, with a doctoral degree.
As at the press time, the market value of Cathay Biotech was 48.9 billion yuan.
(By Lan Suying)
Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.